SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-040661
Filing Date
2023-08-09
Accepted
2023-08-09 16:30:36
Documents
90
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q fdmt-20230630.htm   iXBRL 10-Q 3587968
2 EX-31.1 fdmt-ex31_1.htm EX-31.1 25391
3 EX-31.2 fdmt-ex31_2.htm EX-31.2 25286
4 EX-32.1 fdmt-ex32_1.htm EX-32.1 16039
  Complete submission text file 0000950170-23-040661.txt   12418988

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fdmt-20230630_pre.xml EX-101.PRE 449523
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fdmt-20230630.xsd EX-101.SCH 82659
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT fdmt-20230630_def.xml EX-101.DEF 303517
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT fdmt-20230630_cal.xml EX-101.CAL 47582
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fdmt-20230630_lab.xml EX-101.LAB 574897
84 EXTRACTED XBRL INSTANCE DOCUMENT fdmt-20230630_htm.xml XML 2440946
Mailing Address 5858 HORTON STREET #455 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET #455 EMERYVILLE CA 94608 5105052680
4D Molecular Therapeutics, Inc. (Filer) CIK: 0001650648 (see all company filings)

IRS No.: 473506994 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39782 | Film No.: 231155674
SIC: 2836 Biological Products, (No Diagnostic Substances)